AI Summary & Key Takeaways
AI InsightMedian overall survival is 52 months.
📌 3 Key Takeaways
Abstract
We studied the clinical and pathological data, staging, treatment and survival of patients with high-grade non-Hodgkin's lymphoma. We studied 26 high-grade non-Hodgkin's lymphoma patients who were followed by oncology outpatient clinic of the internal medicine clinic between the years 1997-2002. Median follow-up was 22 months. Median age was 60.5 (15-79) years. Ten (38.5%) patients were stage I, 10 (38.5%) were stage II, 3 (11.5%) were stage III, 3 (11.5%) were stage IV. Six cycles of CHOP (cyclophosphamide, adriamycin, vincristine, prednisolone) regimen was applied to the patients. In addition to CHOP chemotherapy, radiotherapy was applied for 14 (53.8%) cases. After the treatment, objective response was observed in 19 (73.1%) cases. For 7 patients who did not respond or who showed progression, second line chemotherapy was applied. In the follow up, 8 (38.8%) cases were died. Eighteen (69.2%) patients are still followed up. The median disease-free survival is 43 months. Three years disease free survival rate is 63.1%. Median overall survival is 52 months. Three-year overall survival rate is 66.4%. When the cases were classified according to IPI (International Prognostic Index), there was a significant relationship between disease-free survival and overall survival rates (p=0.002, p=0.003, long-rank test). The data obtained from patients that were diagnosed and followed up, as high-grade lymphoma in our hospital is similar to the data in the existing literature.
Özet
Çalışmamızda hastanemizde izlenen "high grade" Hodgkin dışı lenfoma (HDL) hastalarının klinik ve patolojik özelliklerini, tedavi sonuçlarını ve sağkalım sürelerini değerlendirdik. 1997-2000 yıllan arasında onkoloji polikliniğimizde izlenen 26 (kadın/erkek: 16/10) HDL hastasını retrospektif olarak değerlendirdik. Median izlem süresi 22 ay idi. Median yaş, 60.5 (15-79) yıldı. Hastalarımızın 10'u (%38.5) evre I, 10'u (%38.5) evre II, 3'ü (%11.5) evre III, 3'ü (%11.5) ise evre IV idi. Hastalara 6 kür CHOP (siklofosfamid, adriyamisin, vinkristin, prednizolon) kemoterapisi uygulandı. 14 (%53.8) hastaya ek olarak radyoterapi (RT) verildi. Tedavi sonrası objektif yanıt oranı 73.1 (19 olgu) idi. Yanıtsız veya daha sonrasında progresyon gösteren 7 hastaya 2. seri kemoterapi (KT) uygulandı. İzlem süresince 8 (%38.8) hasta öldü. 18 (%69.2) hasta izlenmeye devam edilmektedir. Survi analizinde median hastalıksız yaşam süresi 43 ay, 3 yıllık hastalıksız yaşam % 60.1, median genel sağ kalım süresi 52 ay, 3 yıllık genel sağkalım ise %66.4 olarak bulundu. Hastalar "International Prognostic Index" (IPI)'e göre sınıflandırıldığında, IPI ile hastalıksız sağkalım ve genel sağkalım arasında istatistiksel olarak anlamlı ilişki saptandı (p=0.002, p=0.003, log-rank test). HDL tanısıyla takip edilen hastaların 3 yıllık verileri değerlendirildiğinde literatürle uyumlu bulundu.